DprE1 inhib Trials - LARVOL Sigma

DprE1 inhib

Welcome, Profile Billing Logout

Companies

2 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

quabodepistat (OPC-167832) / Otsuka

NCT05221502: Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Completed

122

RoW

Delamanid + Bedaquiline + OPC-167832 10 mg, Delamanid + Bedaquiline + OPC-167832 30 mg, Delamanid + Bedaquiline + OPC-167832 90 mg, RHEZ

Otsuka Pharmaceutical Development & Commercialization, Inc., Bill and Melinda Gates Foundation

Pulmonary TB

04/24

05/24

NCT05971602: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

Terminated

RoW

Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE), Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS), Isoniazid and Rifampicin (HR)

Bill & Melinda Gates Medical Research Institute, Global Alliance for TB Drug Development, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd.

Pulmonary Tuberculosis

02/25